Therapeutic outcome in invasive aspergillosis

Clin Infect Dis. 1996 Sep;23(3):608-15. doi: 10.1093/clinids/23.3.608.


A review of series of > or = 4 cases of invasive aspergillosis (total, 1,223 cases) was undertaken to establish the crude mortality and rate of response to therapy with amphotericin B in the major at-risk host groups. In association with pulmonary, sinus, and cerebral aspergillosis in immunocompromised patients, the crude mortality rates were 86%, 66%, and 99%, respectively. No untreated patient survived. Among 84 patients treated for 1-13 days, only one survived. Among those with invasive pulmonary aspergillosis treated for > or = 14 days, the response rates to amphotericin B deoxycholate were 83% (in cases of heart and renal transplantation), 54% (leukemia), 33% (bone marrow transplantation) and 20% (liver transplantation). Patients with AIDS mostly received both amphotericin B and itraconazole, and 37% of those treated for > or = 14 days responded to therapy. Substantial variation in outcome from series to series was related to underlying disease status, site of disease, and management. Invasive aspergillosis remains a devastating opportunistic infection despite current treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Amphotericin B / therapeutic use
  • Antifungal Agents / therapeutic use*
  • Aspergillosis / drug therapy*
  • Aspergillosis / mortality
  • Aspergillosis / physiopathology
  • Deoxycholic Acid / therapeutic use
  • Drug Combinations
  • Humans
  • Itraconazole / therapeutic use
  • Opportunistic Infections / drug therapy*
  • Opportunistic Infections / mortality
  • Opportunistic Infections / physiopathology


  • Antifungal Agents
  • Drug Combinations
  • Deoxycholic Acid
  • Itraconazole
  • Amphotericin B
  • amphotericin B, deoxycholate drug combination